Wednesday , April 14 2021

High-throughput platform enables activity mapping



IMAGE

IMAGE: A lysine methyltransferase attached to a substrate. The lighted portion depicts a methyl group.
       view more

Credit: Image courtesy of Dr. Bradley Dickson / Rothbart Laboratory

GRAND RAPIDS, Mich. (Nov. 28, 2018) – A powerful new biochemical platform that works with a family of enzymes.

Published today in Science AdvancesThe new method provides a high-resolution of enzymes, called lysine methyltransferases. Because of their central role in disease and disease.

The platform was developed by Van Andel Research Institute, Scott Rothbart, Ph.D., in collaboration with EpiCypher, Inc.

"This technology helps us to identify protein interaction networks," said Rothbart. "Several inhibitors of these enzymes are currently in the clinical development pipeline for cancer therapy."

Humans have approximately 20,000 genes that contain molecular molecules, which are used for the processing of cells.

Once a protein is used, it's often used in a protein. There are more than 100 different types of amino acids lysine.

Using

.D Our study suggests that "Lysine methylation is just the type of the iceberg, .D said Evan Cornett, Ph.D. "The method used to determine the class of enzymes."

This technology is the latest advance from the collaboration of Rothbart's lab and EpiCypher. The National Institutes of Health (NIH) awards. Commonly known as America's Seed Fund. The SBIR program supports small businesses in the industry. Graduates of the Institute of Science and Technology.

"The beauty of this technology is its simplicity and throughput," said Martis Cowles, Ph.D., EpiCypher's Chief Business Officer and study co-author. "High-throughput inhibitor screening."

###

In addition to Rothbart, Cornett and Cowles, the authors include Bradley M. Dickson, Ph.D, Robert M. Vaughan, Kevin M. Shaw and Philip P. Versluis, the Van Andel Research Institute; Krzysztof Krajewski, Ph.D., University of North Carolina at Chapel Hill; Nicholas Spellmon, Ph.D., and Zhe Yang, Ph.D., of Wayne State University School of Medicine; Andrew Umstead and Irving E. Vega, Ph.D., University of Michigan State; Zu-Wen Sun, Ph.D., EpiCypher; and Joseph Brunzelle, Ph.D., of Argonne National Laboratory.

The National Institute of Health under the award of R35GM124736 (Rothbart), R43GM110869 (Sun) and R44GM112234 (Sun). The national Institutes of Health.

ABOUT VAN ANDEL RESEARCH INSTITUTE

The Van Andel Institute (VAI) is an independent nonprofit research and science organization. Established by Jay and Betty in Van andel in 1996 in Grand Rapids, Michigan; It is a research and research center (VARI), a researcher of genetic, molecular, molecular and cellular origins of cancer. The globe. Learn more by visiting vari.vai.org. 100% To Research, Discovery & Hope®

ABOUT EPICYPHER

A pioneer of epigenetics and chromatin biology, EpiCypher® is a biotechnology company. EpiCypher manufactures and utilizes recombinant "designer" modified nucleosomes (dNucs) histone binding proteins and enzymes, peptides and antibodies, and.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of the news published to EurekAlert! EurekAlert system.


Source link